The population of patients with intermediate-risk prostate cancer are a large and heterogeneous group with highly variable prognoses, which present a challenge to efforts to develop standardized treatment recommendations.
Mitchell S. Anscher, MD, FACR, FACRO, FASTRO
Advertisement
Articles by Mitchell S. Anscher, MD, FACR, FACRO, FASTRO
Advertisement
Latest Updated Articles
- Favorable vs Unfavorable Intermediate-Risk Prostate Cancer: A Review of the New Classification System and Its Impact on Treatment Recommendations
Published: March 16th 2016 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
More Global Expertise and Talent Are Needed to Administer Cell Therapies
2
FDA Grants Priority Review to Enfortumab Vedotin Combo in MIBC Subset
3
Adaptive Treatment and Other Advances May Drive Radiotherapy Field Forward
4
Simultaneous Integrated Boost Radiotherapy Improves PFS in Cervical Cancer
5
